eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 65

Original paper
The value of tumor markers in the diagnosis of papillary thyroid carcinoma alone and in combination

Heng Ma
Sanpeng Xu
Jin Yan
Chao Zhang
Shenghui Qin
Xi Wang
Naping Li

Pol J Pathol 2014; 65 (3): 202-209
Online publish date: 2014/10/18
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
PlumX metrics:
Aim of the study is to evaluate the expression of CK19, galectin-3, HBME-1, CD56, claudin-1 and neutrophil gelatinase-associated lipocalin (NGAL) in papillary thyroid carcinoma (PTC), including classic, follicular variant and micro-carcinoma. Peritumoral benign thyroid tissues were used as a control (C).

Immunohistochemical staining with the EnVision detection system was performed on 59 formalin-fixed, paraffin-embedded thyroid tissues, including 43 PTC and 16 C.

CK19, galectin-3, HBME-1, claudin-1 and NGAL were positive in most PTC, but were negative or showed focal weak staining in C. CD56 was positive in C, but absent in PTC. For a single analyzed tumor marker, the sensitivity of the above six thyroid tumor markers was 100%, 95.3%, 86%, 79.1%, 90.7%, 93%, respectively. The specificity was 56.25%, 100%, 100%, 100%, 100%, 100%, respectively. For the combination of the six tumor markers, the sensitivity, specificity, positive predictive value, negative predictive value and the diagnostic accuracy were all 100%, with co-expression of at least four indices.

In the diagnosis of PTC, combined application of the above tumor markers is recommended. It can be diagnosed as PTC clearly when thyroid lesions are positive for at least four of the above tumor markers [CD56(–)], and can be excluded as PTC definitely when at least four tumor markers are negative [CD56(+)].

papillary thyroid carcinoma, CK19, galectin-3, HBME-1, CD56, claudin-1, NGAL

Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.